Neonatal screening for prenatal alcohol exposure: Assessment of voluntary maternal participation in an open meconium screening program

Alcohol

Volumn 46, Issue 3, 2012, Pages 269-276

  Zelner, Irene ^a,b   Shor, Sarit ^a,b   Lynn, Hazel ^c   Roukema, Henry ^d   Lum, Lisa ^d   Eisinga, Kirsten ^d   Koren, Gideon ^a,b,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Grey Bruce Health Unit   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Developmental follow up; Fatty acid ethyl esters; Fetal alcohol spectrum disorder; Meconium; Neonatal screening

Indexed keywords

ALCOHOL; FATTY ACID ESTER;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; FATTY ACID ANALYSIS; FECES ANALYSIS; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGH RISK PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BEHAVIOR; MECONIUM; NEWBORN; NEWBORN SCREENING; PRENATAL EXPOSURE; PREVALENCE; PUBLIC HEALTH SERVICE; SOCIAL SUPPORT;

ADULT; ALCOHOL DRINKING; BIOLOGICAL MARKERS; CHILD DEVELOPMENT; CHILD, PRESCHOOL; EARLY MEDICAL INTERVENTION; ESTERS; FATTY ACIDS; FEMALE; FETAL ALCOHOL SYNDROME; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INFORMED CONSENT; MECONIUM; NEONATAL SCREENING; ONTARIO; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS; VOLITION;

EID: 84859739898     PISSN: 07418329     EISSN: 18736823     Source Type: Journal    
DOI: 10.1016/j.alcohol.2011.09.029     Document Type: Article

References (41)

1. Bakdash A., Burger P., Goecke T.W., Fasching P.A., Reulbach U., Bleich S., et al. Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. Analytical and Bioanalytical Chemistry 2010, 396:2469-2477.
2. Bearer C.F., Gould S., Emerson R., Kinnunen P., Cook C.S. Fetal alcohol syndrome and fatty acid ethyl esters. Pediatric Research 1992, 31:492-495.
3. Bearer C.F., Jacobson J.L., Jacobson S.W., Barr D., Croxford J., Molteno C.D., et al. Validation of a new biomarker of fetal exposure to alcohol. Journal of Pediatrics 2003, 143:463-469.
4. Bearer C.F., Lee S., Salvator A.E., Minnes S., Swick A., Yamashita T., et al. Ethyl linoleate in meconium: a biomarker for prenatal ethanol exposure. Alcoholism: Clinical & Experimental Research 1999, 23:487-493.
5. Bearer C.F., Santiago L.M., O'Riordan M.A., Buck K., Lee S.C., Singer L.T. Fatty acid ethyl esters: quantitative biomarkers for maternal alcohol consumption. Journal of Pediatrics 2005, 146:824-830.
6. Bertrand J. Interventions for children with fetal alcohol spectrum disorders (FASDs): overview of findings for five innovative research projects. Research in Developmental Disabilities 2009, 30:986-1006.
7. Best C.A., Laposata M. Fatty acid ethyl esters: toxic non-oxidative metabolites of ethanol and markers of ethanol intake. Frontiers in Bioscience 2003, 8:e202-e217.
8. Brien J.F., Chan D., Green C.R., Iqbal U., Gareri J., Kobus S.M., et al. Chronic prenatal ethanol exposure and increased concentration of fatty acid ethyl esters in meconium of term fetal Guinea pig. Therapeutic Drug Monitoring 2006, 28:345-350.
9. Burd L., Hofer R. Biomarkers for detection of prenatal alcohol exposure: a critical review of fatty acid ethyl esters in meconium. Birth Defects Research Part A Clinical and Molecular Teratology 2008, 82:487-493.
10. Chan D., Bar-Oz B., Pellerin B., Paciorek C., Klein J., Kapur B., et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Therapeutic Drug Monitoring 2003, 25:271-278.
11. Chudley A.E., Conry J., Cook J.L., Loock C., Rosales T., LeBlanc N. Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. Canadian Medical Association Journal 2005, 172:S1-S21.
12. Derauf C., Katz A.R., Frank D.A., Grandinetti A., Easa D. The prevalence of methamphetamine and other drug use during pregnancy in Hawaii. Journal of Drug Issues 2003, 33:1001-1016.
13. Etchells E., Sharpe G., Walsh P., Williams J.R., Singer P.A. Bioethics for clinicians: 1. Consent. Canadian Medical Association Journal 1996, 155:177-180.
14. Flagler E., Baylis F., Rodgers S. Bioethics for clinicians: 12. Ethical dilemmas that arise in the care of pregnant women: rethinking " maternal-fetal conflicts" Canadian Medical Association Journal 1997, 156:1729-1732.
15. Garcia-Algar O., Kulaga V., Gareri J., Koren G., Vall O., Zuccaro P., et al. Alarming prevalence of fetal alcohol exposure in a Mediterranean city. Therapeutic Drug Monitoring 2008, 30:249-254.
16. Gareri J., Lynn H., Handley M., Rao C., Koren G. Prevalence of fetal ethanol exposure in a regional population-based sample by meconium analysis of fatty acid ethyl esters. Therapeutic Drug Monitoring 2008, 30:239-245.
17. Gifford A.E., Farkas K.J., Jackson L.W., Molteno C.D., Jacobson J.L., Jacobson S.W., et al. Assessment of benefits of a universal screen for maternal alcohol use during pregnancy. Birth Defects Research Part A Clinical and Molecular Teratology 2010, 8:838-846.
18. Goh Y.I., Chudley A.E., Clarren S.K., Koren G., Orrbine E., Rosales T., et al. Development of Canadian screening tools for fetal alcohol spectrum disorder. Canadian Journal of Clinical Pharmacology 2008, 15:e344-e366.
19. Goh Y.I., Hutson J.R., Lum L., Roukema H., Gareri J., Lynn H., et al. Rates of fetal alcohol exposure among newborns in a high-risk obstetric unit. Alcohol 2010, 44:629-634.
20. Hicks, M. S. (2007). Meconium alcohol and drug screening. Ph.D. Thesis. University of Calgary, Calgary, Alberta.
21. Hopkins R.B., Paradis J., Roshankar T., Bowen J., Tarride J.E., Blackhouse G., et al. Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis. Journal of Studies on Alcohol and Drugs 2008, 69:510-519.
22. Hutson J.R., Aleksa K., Pragst F., Koren G. Detection and quantification of fatty acid ethyl esters in meconium by headspace-solid-phase microextraction and gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies 2009, 877:8-12.
23. Hutson J.R., Magri R., Gareri J.N., Koren G. The incidence of prenatal alcohol exposure in Montevideo Uruguay as determined by meconium analysis. Therapeutic Drug Monitoring 2010, 32:311-317.
24. Hutson J.R., Rao C., Fulga N., Aleksa K., Koren G. An improved method for rapidly quantifying fatty acid ethyl esters in meconium suitable for prenatal alcohol screening. Alcohol 2011, 45:193-199.
25. Jacobson S.W. Meconium fatty acid ethyl esters (FAEEs) as predictors of severity of fetal alcohol spectrum disorder. Alcoholism: Clinical & Experimental Research 2006, 30:S175.
26. Klein J., Karaskov T., Korent G. Fatty acid ethyl esters: a novel biologic marker for heavy in utero ethanol exposure: a case report. Therapeutic Drug Monitoring 1999, 21:644-646.
27. Koren G., Hutson J., Gareri J. Novel methods for the detection of drug and alcohol exposure during pregnancy: implications for maternal and child health. Clinical Pharmacology & Therapeutics 2008, 83:631-634.
28. Littner Y., Cudd T.A., O'Riordan M.A., Cwik A., Bearer C.F. Elevated fatty acid ethyl esters in meconium of sheep fetuses exposed in utero to ethanol-a new animal model. Pediatric Research 2008, 63:164-168.
29. McNamara T.K., Orav E.J., Wilkins-Haug L., Chang G. Risk during pregnancy-self-report versus medical record. American Journal of Obstetrics & Gynecology 2005, 193:1981-1985.
30. Marcellus L. Is meconium screening appropriate for universal use? Science and ethics say no. Advances in Neonatal Care 2007, 7:207-214.
31. Moore C., Jones J., Lewis D., Buchi K. Prevalence of fatty acid ethyl esters in meconium specimens. Clinical Chemistry 2003, 49:133-136.
32. Noland J.S., Singer L.T., Arendt R.E., Minnes S., Short E.J., Bearer C.F. Executive functioning in preschool-age children prenatally exposed to alcohol, cocaine, and marijuana. Alcoholism: Clinical & Experimental Research 2003, 27:647-656.
33. Ontario Ministry of Health and Long-Term Care. Healthy babies healthy children report card. 6-1-2003. Accessed 25.07.10. http://www.health.gov.on.ca/english/public/pub/ministry_reports/healthy_babies_report/hbabies_report.html.
34. Peadon E., Rhys-Jones B., Bower C., Elliott E.J. Systematic review of interventions for children with fetal alcohol spectrum disorders. BMC Pediatrics 2009, 9:35.
35. Peterson J., Kirchner H.L., Xue W., Minnes S., Singer L.T., Bearer C.F. Fatty acid ethyl esters in meconium are associated with poorer neurodevelopmental outcomes to two years of age. Journal of Pediatrics 2008, 152:788-792.
36. Public Health Agency of Canada HIV/AIDS epi updates August 2006 2006, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada.
37. Russell M., Martier S.S., Sokol R.J., Mudar P., Bottoms S., Jacobson S., et al. Screening for pregnancy risk-drinking. Alcoholism: Clinical & Experimental Research 1994, 18:1156-1161.
38. Sampson P.D., Streissguth A.P., Bookstein F.L., Little R.E., Clarren S.K., Dehaene P., et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 1997, 56:317-326.
39. Stade B., Ali A., Bennett D., Campbell D., Johnston M., Lens C., et al. The burden of prenatal exposure to alcohol: revised measurement of cost. Canadian Journal of Clinical Pharmacology 2009, 16:e91-e102.
40. Streissguth A.P., Bookstein F.L., Barr H.M., Sampson P.D., O'Malley K., Young J.K. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. Journal of Developmental & Behavioral Pediatrics 2004, 25:228-238.
41. Streissguth A.P., O'Malley K. Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. Seminars in Clinical Neuropsychiatry 2000, 5:177-190.